Xellia Pharmaceuticals Private Limited, a active private limited company, was established on 13 September 2010 in Bangalore, Karnataka, India. Engaging in business support services within the professional, scientific and technical sector, it holds CIN: U24230KA2010PTC055122. Registered under ROC Roc Bangalore. it is unlisted. It has an authorized capital of ₹1.00 Cr and a paid-up capital of ₹0.10 M.
It upholds a compliant status. Employing 52 professional, Its leadership includes Vidya Viswanathan (Director), Soren Hostrup (Director). Past directors included Vinod Gajanan Naik, Rajeev Kumar Khurana, Bente Schmidt Nielsen. Its latest AGM occurred on 28 August 2025, with the balance sheet filed on 31 March 2025. It is based at Unit Ps-9, Tower 2, 8Th Floor Of M/S. Sumadhura Capitol Towers Pvt Ltd, Sy. No. 14 & 158, Pattandur Agrahara Village, K R Puram Hobli, Bengaluru East, Bengaluru, Bangalore, Karnataka, 560066.
U24230KA2010PTC055122
055122
13 September 2010
₹1.00 Cr
₹0.10 M
Roc Bangalore
Unlisted
Active
Explore comprehensive insights into Xellia Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vidya Viswanathan | Director | 01 Feb 2020 | Current |
| Soren Hostrup | Director | 20 Aug 2024 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 10 Mar 2011 | Past |
| Pramod Abcsdd | Managing Director | 06 Jan 2019 | Past |
| Pramod Abcsdd | Additional Director | 18 Jun 2012 | Past |
| Pramod Abcsdd | Director | 10 Mar 2011 | Past |
| Pramod Abcsdd | Additional Director | 30 Sep 2020 | Past |
| Pramod Abcsdd | Additional Director | 02 Sep 2024 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Xellia Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 22.19% increase. The company also saw a substantial improvement in profitability, with a 24.4% increase in profit. The company's net worth Soared by an impressive increase of 21.26%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Xellia Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
There are no open charges registered against the company as per our records.
Xellia Pharmaceuticals has a workforce of 52 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Xellia Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xellia Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Xellia Pharmaceuticals Private Limited last Annual general meeting of members was held on 28 Aug 2025 as per latest MCA records. was documented.
The activity Xellia Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore. was completed.
Progress on Soren Hostrup was appointed as a Director was appointed as a Director on 20 Aug 2024 & has been associated with this company since 1 year 3 months . was documented.
The activity Vidya Viswanathan was appointed as a Director was appointed as a Director on 01 Feb 2020 & has been associated with this company since 5 years 9 months . was completed.
Xellia Pharmaceuticals Private Limited was registered on 13 Sep 2010 with Roc Bangalore & aged 15 years 2 months as per MCA records. was recorded as a recent event.
The CIN of Xellia Pharmaceuticals Private Limited is U24230KA2010PTC055122.
Xellia Pharmaceuticals Private Limited is headquartered at Unit Ps-9, Tower 2, 8Th Floor Of M/S. Sumadhura Capitol Towers Pvt Ltd, Sy. No. 14 & 158, Pattandur Agrahara Village, K R Puram Hobli, Bengaluru East, Bengaluru, Bangalore, Karnataka, 560066.
Xellia Pharmaceuticals Private Limited was incorporated on 13 September 2010.
The current directors of Xellia Pharmaceuticals Private Limited are
The primary industry of Xellia Pharmaceuticals Private Limited is Professional, Scientific And Technical.
Xellia Pharmaceuticals Private Limited is unlisted.
The authorized capital of Xellia Pharmaceuticals Private Limited is ₹1.00 Cr, and the paid-up capital is ₹0.10 M.
The compliance status of Xellia Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX